HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Comparison of the immunogenicity and reactogenicity of two commercially available hexavalent vaccines administered as a primary vaccination course at 2, 4 and 6 months of age.

Abstract
Infants (N = 459) were randomly assigned to receive either Infanrix hexa or Hexavac vaccines at 2, 4 and 6 months of age as a primary vaccination schedule. The immunogenicity of the hepatitis B component was statistically significantly higher for Infanrix hexa compared to Hexavac in terms of both seroprotection (98.6% versus 94.7%, p = 0.0302) and GMCs (905.6 versus 226.4, p < 0.0001). Significantly (p < or =0.0001) higher antibody levels against diphtheria and the 3 polio components were also induced by Infanrix hexa. The responses to tetanus, Hib and pertussis components were similar. The incidences of clinically relevant solicited symptoms, unsolicited symptoms or serious adverse events were low in both groups.
AuthorsI Tichmann, H Preidel, D Grunert, S Habash, R Schult, R Maier, P K Gildberg, H-C Sengespeik, F Meurice, R Sänger
JournalVaccine (Vaccine) Vol. 23 Issue 25 Pg. 3272-9 (May 09 2005) ISSN: 0264-410X [Print] Netherlands
PMID15837232 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies, Bacterial
  • Antibodies, Viral
  • Vaccines, Combined
Topics
  • Antibodies, Bacterial (analysis, biosynthesis)
  • Antibodies, Viral (analysis, biosynthesis)
  • Female
  • Germany
  • Humans
  • Immunization Schedule
  • Infant
  • Male
  • Single-Blind Method
  • Vaccines, Combined (administration & dosage, adverse effects, immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: